Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Solana Company - Class A Common Stock (NQ:HSDT)

14.64 -1.43 (-8.90%)
Streaming Delayed Price Updated: 1:18 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Solana Company - Class A Common Stock

< Previous 1 2 3 4 Next >
Solana Company (NASDAQ:HSDT) Selects BitGo as Custodian for SOL Treasury Holdings
From BitGo
Via Business Wire
Preeminent SOL Treasury Vehicle, Solana Company (NASDAQ:HSDT), Adds Coinbase, BitGo, and Anchorage Digital as Custodians
From Solana Company
Via GlobeNewswire
Solana Company (NASDAQ:HSDT), Formerly Helius, Continues Amassing SOL, the Native Asset of Solana Blockchain
From Solana Company
Via GlobeNewswire
Preeminent SOL Treasury Company Helius (NASDAQ:HSDT) Announces Corporate Name Change to Solana Company and Letter of Intent with Solana Foundation
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Announces FDA 510(k) Submission for PoNS® Device Label Expansion in Stroke
Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device Designation 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius (NASDAQ:HSDT) Begins Purchases of SOL, the Native Asset of Solana Blockchain
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Announces Positive Outcome of the Portable Neuromodulation Stimulator PoNS® Stroke Registrational Program and Upcoming Submission to FDA Under Breakthrough Designation
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Compliant with Nasdaq’s Continued Listing Requirements
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies Announces Reverse Stock Split
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Small-Cap Disruptors KZIA, SNYR, HSDT, TRNR, PRSO Lead Momentum – More Microcap Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria
Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq’s Equity Rule requirement 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting
Shepherd Center’s Dr. Deborah Backus to Showcase Final Results of PoNSTEP Study, Providing New Insight into Maximizing Impact of Neuromodulation to Improve Gait in People with MS 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces Reimbursement by Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device
United Healthcare approves claim for PoNS Device at out-of-network adjusted list price, becoming the second payer to join Anthem in providing PoNS reimbursement 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies Announces Reverse Stock Split
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. (NASDAQ: HSDT) Featured in Coverage of the 37th Annual ROTH Conference
Via Investor Brand Network
Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $3.7 Million Gross Proceeds Priced At-the-Market
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces Strong Enrollment of its Stroke Pivotal Study Exceeding Initial Target
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Announces First Portable Neuromodulation Stimulator (PoNS®) System Sale to the Veterans Affairs (VA) Healthcare System
Initial order placed with Company’s distributor at contracted price and represents operational implementation through VA Federal Supply Schedule (FSS) Contract 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device
Management to host business update call today at 9:00am ET 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces Exploration of Strategic Alternatives
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Dane Andreeff, CEO of Helius Medical Technologies Inc. (NASDAQ: HSDT), to Present at NobleCon20
Via Investor Brand Network
Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study
From Helius Medical Technologies, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.